Evotec SE stock (DE0005664809): valuation in focus after May voting-rights update

Evotec SE shares traded higher in Germany on 05/29/2026 as investors digested a fresh total-voting-rights notification and continued to debate valuation following the group’s recent balance-sheet measures ahead of the June annual general meeting in Hamburg.

Evotec SE shares traded firmer on Xetra in Germany on 05/29/2026, with the stock quoted around 5.23 EUR at midday, up roughly 2.9 percent versus the previous close of 5.09 EUR, according to finanzen.net as of 05/29/2026.

The Hamburg-based biotechnology company, whose shares are primarily listed on Xetra under the ticker EVT and form part of the German market universe, has been in focus for domestic investors after a recent convertible bond placement and a new notification on the total number of voting rights, both relevant ahead of the annual general meeting scheduled in Germany for 06/11/2026.

According to an Evotec SE total-voting-rights announcement published via EQS News on 05/22/2026, the company disclosed the current aggregate number of voting rights pursuant to section 41 of the German Securities Trading Act (WpHG), underlining its obligations toward the German regulator BaFin and providing an updated basis for shareholder participation at the upcoming general meeting.

The EQS notification listed Evotec’s registered office at the Manfred Eigen Campus in Hamburg and reiterated the corporate website as the primary information hub, with the disclosure framed explicitly as a Europe-wide dissemination of the total number of voting rights, according to EQS News as of 05/22/2026.

In parallel, Evotec SE’s capital structure has been shaped by a recent 116.1 million euro convertible bond transaction, which strengthened the balance sheet and is one of the key elements highlighted in investor discussions about valuation ahead of the 06/11/2026 AGM, as summarized in an overview article on ad-hoc-news.de referring to the bond placement and the capital structure context.

On the German market, the share price behavior on 05/29/2026 follows a period of higher volatility, with the stock moving at comparatively low absolute levels versus earlier years, which puts additional emphasis on metrics such as enterprise value and forward multiples for investors analyzing Evotec SE as a research and development partner in the life sciences sector.

For context, international trading in Evotec SE’s equity also includes U.S. over-the-counter instruments, but the German Xetra listing remains the primary price anchor for domestic and many European investors when assessing the company’s valuation, liquidity profile, and corporate actions.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Evotec
• Sector/industry: Drug discovery and biotechnology services
• Headquarters/country: Hamburg, Germany
• Core markets: Europe, North America, selected Asia-Pacific pharma hubs
• Key revenue drivers: Collaborative drug discovery alliances, integrated research services, and milestone- and royalty-bearing partnerships with pharmaceutical and biotech companies
• Home exchange/listing venue: Xetra (EVT)
• Trading currency: EUR

Evotec SE: core business model

Evotec pursues a partnership-led drug discovery model, generating revenue by providing integrated research platforms to pharmaceutical and biotech clients and sharing in the potential upside through milestones and royalties from partnered projects.

Valuation metrics and multiples for Evotec SE

Valuation discussions around Evotec SE have intensified as the share price on Xetra trades in the mid-single-digit euro range, while analysts and investors evaluate how the company’s R&D pipeline, partnership portfolio, and capital structure translate into standard equity metrics such as price-to-sales and enterprise-value-based ratios.

According to finanzen.net on 05/29/2026, the stock was priced at approximately 5.23 EUR during the Friday midday session on Xetra, implying a market capitalization in the low single-digit billion euro range, and analyst estimates cited by finanzen.ch indicate that the company is expected to post a loss per share of about -0.672 EUR for 2026, a factor that leads market participants to focus more on sales multiples, pipeline optionality, and the cash position rather than near-term earnings-based valuation measures.

Conclusion

With Evotec SE’s share price on Xetra trading moderately higher on 05/29/2026 and a fresh disclosure of the total number of voting rights ahead of the 06/11/2026 annual general meeting, German investors can anchor their view in updated governance and capital-structure data when assessing the stock.

The current valuation debate, shaped by single-digit euro share prices, a recent 116.1 million euro convertible bond, and expectations for a 2026 loss per share, centers on how the company’s drug discovery partnerships and long-term pipeline potential might be reflected in future multiples and market capitalization without implying any specific investment stance.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.